Company intelligence / Profile preview

Gradient Denervation Technologies

Suresnes, Île-de-France, Francegradientdenervation.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Gradient Denervation Technologies is developing a minimally invasive, ultrasound-based catheter device for the treatment of pulmonary hypertension in heart failure patients. The company’s lead program has received FDA Breakthrough Device Designation and is currently enrolling patients in an early feasibility study (PreVail-PH2). Initial first-in-human studies began in 2023. There are no approved drug or device therapies for this patient group in the US[8][9].

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Surgical Medical Devices

Partnerships

Sofinnova Partners/MD Start III Fund (incubation and investment)[2][6]Stanford University Biodesign Program/IP licensing[6]

Beyond the preview

Go deeper on Gradient Denervation Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gradient Denervation Technologies.

Explore the full profile